Please login to the form below

Not currently logged in
Email:
Password:
I have forgotten my password

NPS

This page shows the latest NPS news and features for those working in and with pharma, biotech and healthcare.

Shire finally bags EU approval for rare disease drug Natpar

Shire finally bags EU approval for rare disease drug Natpar

Natpar was one of the primary reasons Shire forked out $5.2bn to buy NPS Pharma in 2015 just before the FDA gave its go-ahead for the new therapy, which

Latest news

More from news
Approximately 3 fully matching, plus 16 partially matching documents found.

Latest Intelligence

  • Digital mania - a question of value Digital mania - a question of value

    So bad in fact, that the best Net Promoter Score (NPS) is a whopping -40% (minus!).

  • A rare talent A rare talent

    Before that the firm had a busy 2015, buying US rare disease-focused biotech NPS Pharma for $5.2bn and rare disease and gastrointestinal company Meritage Pharma for at least $70m

  • Deal Watch table for January 2015 Deal Watch table for January 2015

    NPS/Shire. NPS specialises in rare diseases including Gattex [teduglutide] for the treatment of short bowel syndrome.

  • Pharma deals during January 2015 Pharma deals during January 2015

    Top of the table was the all cash acquisition of NPS Pharmaceuticals by Shire for a total of $5.2bn just one year on from its acquisition of ViroPharma.

  • Pharma deals during June 2014 Pharma deals during June 2014

    Hot gossip. Rumours were posted by the Financial Times that Shire was about to make a $5bn bid for NPS Pharmaceuticals. ... So strong were the rumours that this led to NPS issuing an official denial.

More from intelligence
Approximately 0 fully matching, plus 6 partially matching documents found.

Latest appointments

  • CRISPR Therapeutics appoints Dr Tony Coles CRISPR Therapeutics appoints Dr Tony Coles

    He has also previously held executive and leadership positions at NPS Pharmaceuticals, Vertex Pharmaceuticals, Bristol-Myers Squibb and Merck &Co.

  • Patrick Fabbio named CFO at electroCore Patrick Fabbio named CFO at electroCore

    Patrick Fabbio named CFO at electroCore. He joins from NPS Pharmaceuticals where he was VP finance. ... Fabbio has over 20 years of financial leadership experience in public and private life science and pharmaceutical companies, most recently as VP

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

  • Packer Forbes News December 2015

    Think NP-C’ campaign, the Packer Forbes team in collaboration with the INPDA and Actelion were delighted to be shortlisted as a finalist for the prestigious Pharmaceutical Market Excellence Awards (PMEA) ... Think NP-C’ campaign, which works towards

  • Packer Forbes News March 2016

    The international Think Again. Think NP-C campaign, which encourages clinicians to recognise and link the symptoms of the rare and devastating disease, Niemann-Pick Type C (NP-C), has been ... Think NP-C has been acknowledged for its significant impact

  • Four Health Communications

    We are particularly proud to have launched European HIV-Hepatitis Testing Week and Think Again, Think NP-C, which have been independently recognised with industry awards and, more importantly, improved the

More from PMHub
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
infill healthcare communication

infill is a dynamic and innovative, international healthcare agency with >25 years' experience in delivering healthcare communication, medical education and...

Latest intelligence

No incentive for a cure
The paradox of ‘cost-effective but unaffordable’ life-saving medicines...
Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...

Quick links

Infographics

Multimedia